Targeted Therapy, Blog

CML Treatment: Imatinib vs Dasatinib vs Ponatinib vs Asciminib

Medically reviewed by Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center. Last reviewed: [September 2026] Chronic myeloid leukemia (CML) treatment is built around daily tablets called tyrosine kinase inhibitors (TKIs), which block the BCR-ABL protein (written BCR::ABL1 in…

Salma Abdel, Evidence-Based Medical Researcher
September 30, 2026

Blog, Targeted Therapy

Multiple Myeloma Treatment: Drugs, Regimens and How They Are Sequenced

Written by Salma Abdel. Medically reviewed by Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center. Last reviewed: [September 2026] Multiple myeloma treatment combines drugs from different classes, usually three or four at a time, and is given in…

Salma Abdel, Evidence-Based Medical Researcher
September 25, 2026

Blog, Non-small Cell Lung Cancer Targeted Therapy

Biomarker Testing in Lung Cancer: How Your Results Decide Treatment

Medically reviewed by Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center. Last reviewed: [SEPTEMBER-2026] Lung cancer biomarker testing checks a sample of the tumor, or sometimes blood, for gene changes and proteins that drive the cancer. In non-small…

Salma Abdel, Evidence-Based Medical Researcher
September 25, 2026

Blog, Breast Cancer, HER2-Negative (HER2-), HR+ Breast Cancer

Palbociclib and Fulvestrant for Advanced Breast Cancer: Benefits, Survival Data and Side Effects

Palbociclib and Fulvestrant Treatment calender

Medically reviewed by: Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center Published: July 2026 · Last medically reviewed: July 2026 · This page provides general education about a specific treatment combination. It does not replace individualized advice from…

Salma Abdel, Evidence-Based Medical Researcher
July 22, 2026

Blog

Fulvestrant Injection: How It Works, Dosing, and What to Expect

Medically Reviewed by: Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center Fact-Checked by: Generic Oncology Editorial Team Reviewed: July 2026 Hearing a new drug name for the first time is disorienting, especially when it comes wrapped up in…

Salma Abdel, Evidence-Based Medical Researcher
July 21, 2026

Non-small Cell Lung Cancer Targeted Therapy

Progression After Osimertinib: Understanding Resistance and Your Next Treatment Options

Patient with Progression After Osimertinib

Life After Tagrisso Does Not Follow One Universal Path Medically reviewed by: [Salma Mamdouh Elreedy, clinical oncologist]Last reviewed: [05-07-2026]Next review due: [05-01-2027] Geographic note: Drug approvals mentioned in this article primarily refer to the United States. Treatment availability and recommended…

Salma Abdel, Evidence-Based Medical Researcher
July 5, 2026

Blog

Managing Osimertinib Side Effects: A Guide to Osimert Safety

Osimertinib, widely known by its brand name Tagrisso, represents a major advancement in oncology. It is a highly specialized pill. Doctors prescribe it for specific types of non-small cell lung cancer. Specifically, it targets tumors with certain genetic mutations. These…

Salma Abdel, Evidence-Based Medical Researcher
June 30, 2026

Blog

Ibrutinib Side Effects: What to Expect and When to Call Your Doctor

IBRUTINIB PATIENT EDUCATION | Last reviewed: June 2026 | Medical reviewer: [Salma Mamdouh Elreedy] Ibrutinib (brand name: Imbruvica) is an oral targeted therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s…

Salma Abdel, Evidence-Based Medical Researcher
June 29, 2026

Blog

Bevacizumab Biosimilars: A Complete Guide

Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, Jobevne — and What “Biosimilar” Actually Means Patient and Caregiver Reference | Reviewed against FDA approval records and published comparative clinical trial data Last updated: June 2026 | Next scheduled review: June 2027 or upon…

Salma Abdel, Evidence-Based Medical Researcher
June 18, 2026

Breast Cancer, Targeted Therapy

CDK4/6 Inhibitors Explained: Palbociclib, Ribociclib, and Abemaciclib

If your oncologist mentioned a “CDK4/6 inhibitor,” you’re probably left wondering what those letters even mean. Here’s a plain walkthrough of how these pills work, how the three options differ, what to expect, and what your choices are if cost…

Salma Abdel, Evidence-Based Medical Researcher
June 12, 2026

Trending now